Speakers
You-Yeon Won
Chief Scientific Officer
Spirrow Therapeutics
Day Two
Thursday – July 15, 2021
2:30 pm | Polymer Lung Surfactant: A First-in-Kind Synthetic Surfactant Therapeutic for ARDS
Mark Andrew Borden
Director, Biomedical Engineering
Respirogen
Day Two
Thursday – July 15, 2021
3:00 pm | Respirogen Oxygen Microbubble Therapy in ARDS
Oren Hershkovitz
Chief Executive Officer
Enlivex
Day Two
Thursday – July 15, 2021
3:30 pm | Allocetra, a Novel Macrophage Reprogramming Cell Therapy Being Developed for the Treatment of Inflammatory Diseases Including Sepsis, COVID-19 and ARDS
Eric Jenkins
Senior Medical Director
Athersys
Day One
Wednesday – July 14, 2021
9:00 am | Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS
Day Two
Thursday – July 15, 2021
2:00 pm | Blinded by the Light: Looking Past Mortality to Negotiate Clinically Relevant and Achievable ARDS Trial Endpoints
Melanie Kelly
Chief Scientific Officer
Tetra Biopharma
Day Two
Thursday – July 15, 2021
9:00 am | Development of Novel Injectable and Inhaled Cannabinoid Drugs for Systemic Inflammation and ARDS
Nina Patel
Director, Clinical Development & Medical Affairs ILD
Boehringer Ingelheim
Shamsah Kazani
Senior Medical Director
Alexion Pharmaceuticals
Natacha Le Moan
Senior Director - Translational Research
Catalyst Biosciences
Tim Higenbottam
President
Faculty of Pharmaceutical Medicine
Day One
Wednesday – July 14, 2021
9:00 am | Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS
8:00 am | Outlining How the Pandemic Has Transformed the ARDS Drug Development Landscape & Contextualising Key Updates in ARDS Drug Development Over the Past 12 Months
Brijesh Patel
Clinical Senior Lecturer in Cardiothoracic
Imperial College London
Day One
Wednesday – July 14, 2021
9:00 am | Panel Discussion: Deep Diving into the Failures of COVID-19 Related ARDS Clinical Trials to Learn How to Avoid Common Mistakes & Streamline the Development of Clinically Effective Therapeutics for COVID-19 ARDS
8:30 am | Analyzing the Pathology & Molecular Mechanisms Behind COVID-19 Associated ARDS to Determine Which Indicators Best Predict Onset of Severe ARDS & COVID-19 Pneumonia
David Thickett
Professor of Respiratory Medicine
University of Birmingham
Day One
Wednesday – July 14, 2021
10:30 am | Translating Lessons Learned From COVID-19 Associated ARDS to Non-COVID-19 Associated ARDS: Leveraging the Latest Research to Strategize Drug Development Against ARDS
Pablo Pelegrin
Scientific Deputy Director & Principal Investigator
Biomedical Research Institute of Murcia
Day One
Wednesday – July 14, 2021
11:30 am | Molecular Mechanisms of the ARDS Inflammatory Response in COVID-19 for Drug Development
Joe Garcia
Chief Executive Officer
Aqua Lung Therapeutics
Day One
Wednesday – July 14, 2021
1:30 pm | DAMPening ARDS & VILI Inflammation with a Novel Biologic Targeting eNAMPT
Kenneth Adler
Professor
Biomarck Pharmaceuticals
Day One
Wednesday – July 14, 2021
2:00 pm | An Inhaled Inhibitor of MARCKS Improved Oxygenation & Reduced Mortality in ARDS Patients
Jessie Huang
Post-Doctoral Associate
Boston University
Day Two
Thursday – July 15, 2021
9:30 am | Investigating Stem Cell-Based Modelling for Understanding COVID-19 Pathogenesis & Therapeutics
Danny McAuley
Clinical Professor
Queens University Belfast
Day Two
Thursday – July 15, 2021
10:00 am | Deep Diving into Modelling for ARDS: Using Human Models to Predict the Pathophysiology of ARDS in COVID-19/None COVID-19 Patients & Accelerate Drug Development
Juho Jalkanen
Vice President Business Development
Faron Pharmaceuticals
Day Two
Thursday – July 15, 2021
1:30 pm | Designing & Developing ARDS Clinical Trials From Concept to Clinic: Understanding What Parameters You Must Consider to Optimize the Success of Your Therapeutic in a Clinical Setting
Seung-Yong Seong
Co-Chief Executive Officer
Shaperon
Day Two
Thursday – July 15, 2021
12:00 pm | Damage-Associated Molecular Pattern (DAMPs) for ARDS by COVID-19: From the Basic Immunology to Phase 2 Clinical Trial
Miguel Forte
Chief Executive Officer
Bone Therapeutics
Day One
Wednesday – July 14, 2021
7:55 am | Chair’s Opening Remarks
Anthony Ting
Vice President of Regenerative Medicine & Head of Cardiopulmonary Programs
Athersys
Day Two
Thursday – July 15, 2021
8:55 am | Chair’s Opening Remarks
Bernhard Fischer
Chief Executive Officer
Apeptico
Day One
Wednesday – July 14, 2021
3:30 pm | A Novel Targeted Inhaled Therapy for Treatment of ARDS by Reducing Extravascular Lung Water
Marcelo Hill
Chief Scientific Officer
ARDAN Pharma
Day One
Wednesday – July 14, 2021
12:00 pm | Targeting Inflammasomes to Control Coronavirus-Induced T cell Dysfunction
Harry Karmouty
Assistant Professor
Tenure Track at The University of Texas Health Science Center at Houston (UTHealth)
Day One
Wednesday – July 14, 2021
11:00 am | Elevated Hyaluronan in ARDS Associated With COVID-19
Aprile Pilon
President & Chief Executive Officer
Trove Therapeutics
Day One
Wednesday – July 14, 2021
4:30 pm | Therabron (rhCC10 protein): A Host-Targeted Multi-Modal Therapy to Prevent and Treat ARDS
Ritu Lal
Chief Executive Officer
GEn1E Lifesciences
Day One
Wednesday – July 14, 2021
5:00 pm | GEn1E Lifesciences: A Platform for Advancing Treatments for Rare Inflammatory Diseases
Racheli Ofir
Vice President - Research & IP
Pluristem Therapeutics
Day One
Wednesday – July 14, 2021